American Association for Cancer Research
15357163mct170200-sup-179899_3_supp_4462166_p182wf.pptx (635.04 kB)

Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein

Download (635.04 kB)
posted on 2023-04-03, 15:09 authored by Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du, Melissa Damschroder, Hui Feng, Steven Eck, Nicholas Buss, Lolke de Haan, Andrew J. Pierce, Haesun Park, Andrew Sylwester, Michael K. Axthelm, Louis Picker, Nicholas P. Morris, Andrew Weinberg, Scott A. Hammond

Supplementary Figure 1. Immunophenotype of CD4 T effector (Teff) and regulatory (Treg) cells used in Teff/Treg co-cultures. ( Supplementary Figure 2. Flow cytometry panels and gating strategy for analysis of rhesus peripheral T cells. Supplementary Figure 3. Binding of MEDI6383 to OX40 expressing human and NHP T cells. Dot plot representing the percentage of purified, live, PHA/IL-2 activated human CD4.






Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcγRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFκB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies. Mol Cancer Ther; 17(5); 1024–38. ©2018 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager